Table 2.
Days | Treatment | pa | ||||
---|---|---|---|---|---|---|
Probiotic | Placebo | |||||
n | Median (IQR) (pg/mL) | n | Median (IQR) (pg/mL) | |||
TGF-β1 | 10 | 128 | 616.9 (407.5–950.4) | 127 | 617.3 (369.7–853.9) | 0.34 0.33 |
90 | 123 | 438.5 (308.0–661.1) | 124 | 417.4 (269.3–641.8) | 0.27 0.23 |
|
TGF-β2 | 10 | 128 | 909.8 (451.6–1653.8) | 127 | 999.4 (519.0–1517.1) | 0.90 0.83 |
90 | 123 | 599.6 (311.0–1055.1) | 124 | 532.5 (285.9–1144.2) | 0.76 0.69 |
|
TGF-β3 | 10 | 128 | 37.8 (25.3–58.7) | 127 | 35.8 (22.9–57.2) | 0.25 0.33 |
90 | 123 | 29.9 (21.0–42.7) | 123 | 30.8 (18.8–48.7) | 0.95 0.86 |
aThe upper p-value provided is from the regression analysis of the influence of probiotic ingestion on the log transformed TGF beta concentration by, whilst the lower represents the p-value calculated for the effect of treatment allocation after adjusting for maternal atopy, maternal smoking and presence of siblings